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Effect of erythropoietin on anemia of peritoneally dialyzed
anephric rats. The effect of erythropoietin on anemia was studied
in anephric rats undergoing peritoneal dialysis. Both the number
of bone marrow red cell precursors and plasma iron turnover
were markedly depressed in untreated peritoneally dialyzed
anephric animals when compared to peritoneally dialyzed sham-
operated control rats. Anephric rats receiving 2 U of erythro-
poietin per day for 12 days had greater than threefold more bone
marrow red cell precursors and a twofold larger plasma iron turn-
over than did the saline injected anephric rats. There was no sig-
nificant difference in either bone marrow red cell precursors or
plasma iron turnover in the erythropoietin-treated anephric rats
when compared to the nonuremic controls. Although the rats re-
ceiving erythropoietin for 12 days had a significantly higher he-
matocrit (29.5%) than the saline injected uremic rats did (19.0%),
the hematocrit was significantly lower than that found in nonur-
emic control animals, either receiving erythropoietin (48.1%) or
not receiving erythropoietin (41.6%). Our data suggests that
erythropoietin is potentially a useful agent for the treatment of
anemia of chronic renal failure.
Effet de l'erythropoIétine sur l'anémie de rats anéphriques en
dialyse peritonéale. L'effet de l'erythropoIetine sur l'andmie a
dtd dtudié chez des rats anëphriques soumis a Ia dialyse pdriton-
dale. Le nombre de cellules medullaires prdcurseurs d'hdmaties
et aussi le turnover du fer sont nettement diminus chez des rats
anéphriques non traitds soumis a Ia dialyse pdritoneale par rap-
port a des contrôles (reins intacts) soumis aussi a la dialyse. Les
rats andphriques qui recoivent 2 U d'erythropoIdtine par jour
pendant 12 jours ont une augmentation supdrieure a trois fois des
cellules médullaires prdcurseurs d'hématies et un turnover du
fer deux fois plus rapide que les rats anephriques tdmoins. Ii n'y
a pas de difference significative entre les rats anéphriques traitds
et les rats contrôles non urdmiques. Bien que les rats qui ont
recu de l'erythopoIdtine pendant 12 jours aient un hematocrite
significativement supdrieur (29,5%) a celui des rats urdmiques
contróles (19,0%), leur hdmatocrite est significativement in-
ferieur a celui des rats non urdmiques, que ceuxci reçoivent ou
non de l'erythropoIétine (respectivement 48,1% et 41,6%). Nos
observations suggdrent que l'erythropoIdtine est potentiellement
un agent efficace pour le traitement de l'andmie de l'insuffisance
rdnale chronique.
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Since the primary cause of anemia in patients
with chronic renal insufficiency appears to be defi-
ciency of the renal hormone erythropoietin 11, 2],
replacement therapy with this hormone would seem
to be ideal therapy. The acute administration of
erythropoietin to uremic animals and patients has
been shown to elicit an increased reticulocyte count
and an increased RBC iron incorporation [3-81.
Some but not all studies indicate that the response
in uremia is less than that seen in normals [7, 8].
A major problem with currently available prepa-
rations of erythropoietin is contamination with
endotoxin [9]. The relative resistance to the effects
of endotoxin seen in the rat [10] makes it an ideal
species for the study of erythropoietin prior to the
development of an endotoxin-free preparation. We
recently have developed a model by which surgi-
cally anephric rats can be maintained for prolonged
periods of time by peritoneal dialysis. These rats
have an anemia very similar to that seen in patients
with chronic renal insufficiency. In the present stud-
ies, we have used this model to investigate the ef-
fects of the daily administration of erythropoietin
on this anemia.
Methods
Male Sprague-Dawley rats, each weighing be-
tween 300 and 550 g, were nephrectomized (NTX)
in two stages with strict aseptic technique. During
stage one, the left kidney was removed through a
flank incision. A 1.5-cm skin incision was then
made in the dorsal cervical region through which a
peritoneal catheter, identical to that used by Tenck-
hoff [11] with th exception of the dimensions, was
tunneled s.c. to the flank incision. The distal end of
the catheter then was inserted through the flank in-
cision into the peritoneal cavity and advanced into
the scrotum. After closing the two incisions, we
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placed the animal in the supine position and re-
moved both testicles and the surrounding adipose
tissue through a small suprapubic incision. At the
time of bilateral orchiectomy, the distal end of the
peritoneal catheter was withdrawn from the scro-
tum and cut to length so that when replaced into the
scrotum it extended 0.5 cm distal to the base of the
penis. On the first, second, and third postoperative
days, the peritoneal cavity was rinsed through the
peritoneal catheter with 20 ml of peritoneal dialy-
sate containing 10 tg/ml of gentamicin, and the ani-
mals were given 50,000 U of penicillin and 0.25 mg
of streptomycin. One week after the first surgical
procedure, the right kidney was removed through a
flank incision, and starting on the following day,
peritoneal dialysis was performed daily with com-
mercial peritoneal dialysate containing 1.5 g/dl glu-
cose and no potassium. Fifteen peritoneal ex-
changes were done each day over a 6-hour period.
During each exchange, a volume equal to 7.5% of
the animal's weight was infused through 0.22-s Mil-
lipore filter into the peritoneal cavity. Fifteen min-
utes later, the fluid was drawn into a 50-mi gradu-
ated test tube with 100 mm of mercury vacuum. An
attempt to achieve a daily negative balance equal to
7.5% of the body weight of the animal was made,
and the glucose content of the dialysate was in-
creased to 4.25 g/dl during an occasional exchange
if necessary. The animals had free access to Purina
rat chow and tap water. The peritoneal fluid was
cultured daily, and if positive, the animal was dis-
carded.
On day 2, after starting dialysis, serum urea nitro-
gen and hematocrit were determined. On the eighth
anephric day, no dialysis was performed, and fer-
rokinetic studies (vide infra) were carried out. The
animals were killed on day 12, and hematocrit, RBC
59Fe incorporation, serum urea nitrogen, and bone
marrow studies were conducted. The anephric ani-
mals were compared to a group of sham-operated
control rats. The sham-operated animals were dia-
lyzed identically to anephric rats. The anephric rats
were given free access to Purina rat chow, and the
sham-operated controls were match fed. All rats
had free access to tap water.
In the rats receiving erythropoietin, 2 U of sheep
plasma erythropoietin (step 1) (Connaught Labora-
tories, Ontario, Canada) were given s.c. daily after
each dialysis. The rats not receiving erythropoietin
were injected with 0.5 ml of saline. Four groups of
five rats each were studied: (1) NTX + ESF, aneph-
nc rats receiving erythropoietin; (2) NTX — ESF,
anephric rats receiving saline; (3) sham + ESF,
sham-operated rats receiving erythropoietin; and
(4) sham — ESF, sham rats receiving saline.
Ferrokinetic studies. Plasma iron turnover was
determined by a modification of the method Hersh-
ko, Cook, and Finch [12]. Animals were lightly
anesthetized with Inovar-Vet (0.02 mI/l00 g body
wt) (Pittman Moore, Washington Crossing, New
Jersey). Two milliliters of blood were removed from
the retroorbital sinus for plasma iron determination.
Two microcuries of 59Fe-transferrin were then in-
jected i.v. and 20-s.d samples were collected in trip-
licate from the tail vein into heparinized capillary
tubes at 10, 20, 30, 45, 60, 75, and 90 mm after the
injection. The capillary tubes were centrifuged, and
the plasma volume was measured and counted for
59Fe activity. Total plasma volume was determined
by plotting the 59Fe activity on semi log paper and
extrapolating back to zero time counts. Red cell
mass (RCM) was calculated by the following for-
mula:
RCM = plasma volume x HctI — Hct
Plasma iron turnover (PIT) was calculated as de-
scribed by Finch et al [13]. Erythron iron turnover
(EIT) was calculated by the following formula [141:
EIT = PIT — (0.0035 x plasma iron x
plasma volume)
At the time of sacrifice, the red blood cells were
counted for 59Fe activity, and the percent of the in-
jected 59Fe incorporated into the red blood cells was
determined. Previous studies in both normal and
uremic rats in our laboratory have shown that the
maximum incorporation of 9Fe into red blood cells
occurs by the third day in the rat.
The bone marrow was studied by a modification
of the method of LoBue et al [151. Both femurs and
tibias of each animal were removed, split open, and
the available bone marrow aspirated into pre-
weighed capillary tubes. After weighing, the mar-
row was dispersed in 1 ml of 5% normal human
serum albumin, and the total number of nucleated
cells was determined. A smear of the suspension
was made, stained with benzidine-peroxide, and the
percent nucleated cells containing hemoglobin was
determined.
Serum urea nitrogen concentraton was deter-
mined by the urease method [161. Plasma iron con-
centration was determined using Ferrozine reagent
[17].
Statistics. Data were compared using the Mann-
Whitney nonparametric test for unpaired data 1181.
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Results
The food intake averaged 3.1 glday and was not
significantly different between groups. All animals
lost weight. The average daily weight loss of the
four groups over the 12-day period expressed as a
percent of the initial body weight was as follows:
NTX + ESF, 1.51 (sEM) 0.18; NTX — ESF, 1.35
0.191; sham + ESF, 1.68 0.23; sham — ESF,
2.13 0.17. The only significant difference between
groups was with comparison of NTX ESF to
sham — ESF (P < 0.05).
The serum urea nitrogen concentrations on day 2,
8, and 12 postnephrectorny are shown in Table 1.
All anephric animals had markedly elevated values,
and there were no significant differences between
days 2, 8, and 12 in any of the groups.
The hematocrits on day 2, 8, and 12 are shown in
Table 1. On day 2, there was a mild decrease in
hematocrit in the anephric animals as compared to
the sham animals, which was significant only for the
saline-injected rats. During the next 6 days, the
anemia progressed so that on day 8 both anephric
groups had significant depression of the hematocrit
when compared to the appropriate control group.
Although the hematocrit continued to fall in the
control groups, it stabilized in the erythropoietin-
treated rats, and on day 12 it was significantly high-
er (29.5 vs. 19.0, P < 0.01). The sham-operated ani-
mals given erythropoietin had a significant increase
in hematocrit from day 2 to 12, from 41.9 to 48.1 (P
Table 1. Serum urea nitrogen and hematocrit 2, 8, and 12 days
after nephrectomy"
Group
Day
2
SUN
mg/dl
Day
8
Day
12
Hct
%
Day
2
Day
8
Day
12
NTX+ESF
NTX—ESF
Sham+ESF
Sham—ESF
114
123d
18
19
745
98"
16
15
05
107"
16
25
35.9
342d
41.9
40.4
28.7"
250"
45.4
38.2
295'
190"
48.1
41.6
a Values are the means SEM. NTX is nephrectomized; +ESF
and —ESF is receiving or not receiving erythropoietin, respec-
tively.
b P <0.01 compared to sham +ESF.
P < 0.01 compared to NTX—ESF.
"P < 0.01 compared to sham—ESF.
<0.01), whereas the hematocrit did not significant-
ly increase in the saline-injected sham animals.
These changes in hematocrit were the result of
alterations in red cell mass (Table 3). The red cell
mass in the anephric rats given erythropoietin was
significantly larger than it was in the saline-injected
anephric rats, but it was significantly smaller than it
was in the sham groups. An effect of erythropoietin
on the anephric animals was seen also when the
bone marrow was examined (Table 2). The number
of nucleated red cells per lower extremity in the sa-
line-treated anephric animals was only 27% that of
the anephric animals given erythropoietin. There
were no significant differences in the number of red
cell precursors in the anephric animals given
erythropoietin when compared to either sham-oper-
ated group. Although the saline-injected anephric
group had a significant depression of the total nucle-
ated cells per leg, this was due to a decrease in red
cell precursors, as there was no significant dif-
ference in the benzidine-negative nucleated cells in
these animals compared to any of the other groups.
The prevention of bone marrow depression in the
uremic rats by erythropoietin was substantiated by
the ferrokinetic studies. There were no significant
differences in plasma iron concentrations between
the groups. Erythropoietin prevented the decrease
in iron turnover and RBC 9Fe incorporation, which
was seen in the saline-treated anephric animals
(Table 3). Although the method we used to deter-
mine erythron iron turnover has only been validated
for humans (both normal and uremic) [14], it is in-
teresting that the 51% depression seen in the aneph-
Table 2. Bone marrow studies 12 days after nephrectomya
Total
nucleated Nucleated
cells red cells
per leg per leg
Group (x l0) (x J07)
NTX+ESF 10.8 2•52b
NTX—ESF 7.3' 0.69"
Sham+ESF 11.4 2.65
Sham—ESF 12.5 2.22
a Values are the means SEM. See Table 1 for definitions of
abbreviations.
"P <0.01 compared to NTX—ESF.
P <0.05 compared to sham ---ESF.
p < 0.01 compared to sham—ESF.
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Table 3. Ferrokinetic studiesa
Plasma Erythron
Plasma iron iron Erythrocyte Red cell
iron turnover turnover 59Fe incorporation mass
p.g/dl mg/kg/day mg/kg/day % mi/kg
NTX+ESF 210 1.84" 143" 71.20 214b.d
NTX—ESF 200 1.010 0.63e 48.5' 14.0°
Sham+ESF 251 1.92 1.53 70.1 31.4
Sham—ESF 178 1.56 1.28 74.0 24.0
Values are means SEM. Abbreviations are defined in Table 1.
P < 0.05 compared to NTX—ESF.
o P < 0.01 compared to NTX—ESF.
p < 0.05 compared to sham+ESF.
< 0.05 compared to sham —ESF.
'P < 0.01 compared to sham—ESF
nc animals not receiving erythropoietin is consis-
tent with the 69% decrease in number of red cell
precursors found in the marrow.
Discussion
Anemia is one of the most important problems in
patients with chronic renal failure and can be a ma-
jor limiting factor in the rehabilitation of these pa-
tients. Although hemodialysis improves most of the
biochemical abnormalities of chronic renal failure,
it has little effect on this severe anemia [1, 19]. Al-
though androgens have been shown to have a defi-
nite beneficial effect, the average increase in hemo-
globin concentration with their use is small, and
they cause significant side effects [201. The main
cause of anemia of renal failure is a decreased pro-
duction of red blood cells [1, 2]. The primary factor
appears to be a deficiency of the renal hormone
erythropoietin, but other factors include a de-
creased responsiveness of the uremic bone marrow
to erythropoietin [4-6} and uremic inhibitors to
erythropoietin [21, 221. Acute studies have shown
that uremic animals and man will respond to
erythropoietin with an increased number of reticu-
locytes and RBC 59Fe incorporation [3-81.
Recently Anagnostau et al have shown that 5 UI
day of erythropoietin increases the hematocrit and
red cell mass in partially nephrectomized rats {23l.
The magnitude of the increase was equal to that
found in nonuremic rats. Unfortunately, the anemia
in these animals is mild and spontaneously resolves
without treatment.
In contrast to the anemia seen in the partially
nephrectomized rat, a severe anemia similar to that
seen clinically in patients with chronic renal failure
develops in the anephric rat, and there is no amelio-
ration of this anemia in rats maintained by perito-
neal dialysis for up to 1 month. Our studies show
that the daily administration of erythropoietin can
cause continuous stimulation of the bone marrow
and that this results in a significant improvement in
the anemia. Erythropoietin elicited a greater than
threefold increase in the number of red cell pre-
cursors seen in the bone marrow. This stimulation
of bone marrow erythroid activity was confirmed by
the increased plasma iron turnover seen in the
erythropoietin-treated anephric animals. Our re-
sults may have been different if the animals were
made uremic by a method leaving the kidneys in
place.
Our study does not directly address the questions
of the relative sensitivity to erythropoietin of the
uremic bone marrow compared to the nonuremic
bone marrow and the presence or absence of uremic
inhibitors to ESF. Although much larger effects of
erythropoietin on the number of red cell precursors
present in the bone marrow and plasma iron turn-
over were seen in the uremic animals as compared
to the nonuremic animals, it is likely that the
erythropoietin administered to the sham-operated
animals inhibited the release of endogenous
erythropoietin.
The total daily erythropoietin production by the
normal rat is not known. Daily administration of 1.3
to 2.0 U/day will prevent bone marrow suppression
in either hypertransfused, polycythemic, or protein-
depleted rats [24, 25]. Since the bone marrow de-
pression seen in both these animal models is sec-
ondary to decreased erythropoietin production [25],
it has been suggested that 1.5 U/day approximates
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the normal daily erythropoietin production [26]. If
this suggestion is correct, then our study showing a
normalization of the bone marrow with 2 U/day im-
plies that the sensitivity of the uremic bone marrow
to erythropoietin is relatively normal. The fact that
in the control animals the administered erythro-
poietin only caused a small increase in the hemato-
crit, which at the time of sacrifice did not reach sta-
tistically significant difference from the saline in-
jected controls, suggests that the dose given was
not supraphysiologic.
Although the 2 U of erythropoietin per day nor-
malized the bone marrow in our anephric rats, it on-
ly partially corrected the anemia. This could be due
either to a decreased red cell survival or ineffective
erythropoiesis. The RBC '9Fe incorporation of
71.2% seen in the erythropoietin-treated uremic ani-
mals suggests that ineffective erythropoiesis is not
present [13]. Although we did not measure red cell
survival, our data is compatible with others who
have shown that there is a mild decreased red cell
survival seen in chronic renal failure [27]. Whether
higher doses of erythropoietin would completely
correct the anemia remains to be determined.
Erythropoietin appears to be an ideal agent for
the treatment of the anemia of renal failure. Unfor-
tunately, large scale production of erythropoietin is
presently prohibitively expensive, and the currently
available erythropoietin preparations appear to be
contaminated with endotoxin [9]. Although in most
animals endotoxin causes pyrogenic reactions and
possibly decreases the effectiveness of erythro-
poietin [281, the rat is relatively resistant to the ef-
fects of endotoxin [10]. The lack of a significant dif-
ference in the plasma iron of our rats 17 hours after
injection of erythropoietin or saline supports this re-
sistance (Table 3). The same erythropoietin prepa-
ration causes marked depression of plasma iron 15
hours after infusion into normal or uremic sheep
[281. These studies show that if the effects of endo-
toxin can be eliminated, erythropoietin can prevent
the bone marrow depression and partially amelio-
rate the anemia seen in chronic renal failure. At-
tempts to produce an inexpensive, endotoxin-free
preparation of erythropoietin should be encour-
aged.
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